Alzheimer's Drugs Market Report 2026

Alzheimer's Drugs Market Overview

• Alzheimer's Drugs market size has reached to $10.09 billion in 2025 • Expected to grow to $15.4 billion in 2030 at a compound annual growth rate (CAGR) of 8.8% • Growth Driver: Rising Prevalence Of Alzheimer’s Disease To Drive Market Growth • Market Trend: Kisunla Receives Food and Drug Administration (FDA) Approval As First Amyloid Plaque-Targeting Therapy For Early Alzheimer's • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Alzheimer's Drugs Market?

Alzheimer's drugs refer to drugs that aid in managing memory loss, issues with thinking and reasoning, and daily functioning. These drugs are used to treat Alzheimer's disease, a brain disorder that causes memory, reasoning, and learning to gradually diminish. The major drugs for Alzheimer's are donepezil, rivastigmine, galantamine, and memantine. The drug donepezil refers to a member of the class of drugs known as cholinesterase inhibitors. These are sold through several distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used in several applications, such as early to moderate stages and moderate to severe stages.

What Is The Alzheimer's Drugs Market Growth Forecast?

The alzheimer's drugs market size is expected to see strong growth in the next few years. It will grow to $15.4 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to advancements in precision medicine, integration of ai in drug development, expansion of healthcare infrastructure, government support & funding for dementia research, growth of digital health monitoring solutions. Major trends in the forecast period include personalized alzheimer’s therapy development, neuroprotective drug innovations, early diagnosis & screening solutions, combination & multi-target drugs, patient adherence & monitoring solutions.

Global Alzheimer's Drugs Market Segmentation

1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine 2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 3) By Application: Early To Moderate Stages, Moderate To Severe Stages

What Is The Driver Of The Alzheimer's Drugs Market?

The rising prevalence of Alzheimer's disease is expected to propel the growth of the Alzheimer's drugs market going forward. Alzheimer's disease is a neurologic condition that worsens over time and causes both brain shrinkage and cell death. Drugs for Alzheimer's disease are used to treat memory loss, problems with thinking and reasoning, and difficulties with everyday living. Drugs for Alzheimer's can enhance the quality of life and help maintain independence. For instance, in May 2024, according to a report by the Alzheimer’s Association, a US-based nonprofit organization dedicated to Alzheimer's care, support, and research, the number of Americans aged 65 and older diagnosed with Alzheimer's dementia rose from 6.5 million in 2022 to an estimated 6.9 million in 2024. Therefore, the increasing prevalence of Alzheimer's disease is driving the growth of the Alzheimer's drugs industry.

Key Players In The Global Alzheimer's Drugs Market

Major companies operating in the alzheimer's drugs market are AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC, Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc.

Global Alzheimer's Drugs Market Trends and Insights

Major companies in the Alzheimer’s drugs market are developing innovative products, such as amyloid plaque-targeting therapy, to advance treatment options and improve patient outcomes. Amyloid plaque-targeting therapy is a treatment approach for Alzheimer's disease that focuses on reducing or preventing the accumulation of amyloid-beta plaques in the brain. For instance, in June 2024, Eli Lilly and Company, a US-based pharmaceutical company, got approval for Kisunla (donanemab-azbt) from the Food and Drug Administration (FDA), a US-based federal agency for protecting public health. Kisunla (donanemab-azbt) is the first and only amyloid plaque-targeting therapy for early symptomatic Alzheimer's disease. It works by aiding the body in removing excess amyloid plaques from the brain, which are associated with cognitive decline in Alzheimer's patients. Kisunla is administered as an intravenous infusion every four weeks. The initial dosing regimen involves 700 mg for the first three doses, followed by 1400 mg thereafter. Kisunla is specifically indicated for adults with mild cognitive impairment (MCI) and mild dementia stages of Alzheimer's disease, provided they have confirmed amyloid pathology.

What Are Latest Mergers And Acquisitions In The Alzheimer's Drugs Market?

In May 2025, Sanofi, a France-based pharmaceutical company, acquired Vigil Neuroscience, Inc. for $470 million. Through this acquisition, Sanofi aims to strengthen its early-stage Alzheimer’s pipeline by integrating Vigil’s TREM2-targeting therapy VG 3927, a novel approach to modifying disease progression. Vigil Neuroscience, Inc. is a US-based biotechnology company that develops small-molecule therapies for neurodegenerative diseases, including Alzheimer’s disease.

Regional Insights

North Americawas the largest region in the Alzheimer's drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the alzheimer's drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alzheimer's drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Alzheimer's Drugs Market?

The Alzheimer's drugs market consists of sales of cholinesterase inhibitors such as aricept, exelon, and razadyne. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Alzheimer's Drugs Market Report 2026?

The alzheimer's drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the alzheimer's drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.